Clinical Report: FUMO Score Predicts Progression of Graves' Orbitopathy in Graves' Disease
Overview
This study evaluated the FUMO score, combining visual function tests and orbital ultrasound, to predict overt Graves' orbitopathy (GO) in Graves' disease (GD) patients without initial GO. The FUMO score, especially when combined with TRAb and FT3 levels, demonstrated strong predictive accuracy for GO development over 24 months.
Background
Graves' orbitopathy (GO) is an autoimmune condition affecting orbital tissues, commonly associated with Graves' disease (GD). GO manifests through inflammation, glycosaminoglycan accumulation, and adipose tissue expansion, leading to ocular symptoms. Although many GD patients initially lack overt GO, 25-40% develop it during the disease course. Early identification of patients at risk for GO is clinically important to guide monitoring and treatment decisions.
Data Highlights
Parameter
Low Risk Group (FUMO 0-2)
Medium-High Risk Group (FUMO 3-8)
Number of GD patients
Not specified
Not specified
Development of overt GO after 24 months
Less frequent
More frequent
GO activity
Less frequent active GO
More frequent active GO
GO severity
Less moderate-to-severe cases
More moderate-to-severe cases
Predictive model AUC
0.84 (P < .0001)
Positive Predictive Value (PPV)
73%
Negative Predictive Value (NPV)
72%
Key Findings
The FUMO score (0-8 points) integrates visual function and orbital ultrasound findings to stratify GO risk in GD patients without overt GO.
Patients with medium-high FUMO scores (3-8) developed overt GO more frequently and had more active and severe disease compared to low-risk patients.
TRAb levels and the FUMO score were the strongest independent predictors of GO development.
Higher FT3 levels and smoking status also independently increased the risk of GO progression.
The predictive model showed good discrimination (AUC = 0.84) with balanced positive and negative predictive values (~72-73%).
Clinical Implications
The FUMO score offers a practical tool for early identification of GD patients at risk for developing GO, enabling closer ophthalmologic monitoring and tailored management. Combining FUMO with TRAb and FT3 measurements enhances risk stratification, potentially guiding treatment choices to minimize GO progression. This approach supports proactive interventions such as selenium supplementation or avoiding radioactive iodine in high-risk individuals.
Conclusion
Subclinical ocular alterations quantified by the FUMO score reliably predict the onset and severity of Graves' orbitopathy in Graves' disease patients without initial eye involvement. Incorporating this score into clinical practice may improve early risk assessment and patient outcomes.
References
Wiersinga et al 2020 -- Predictors of Graves' Orbitopathy Development
European Thyroid Association Guidelines 2016 -- Management of Graves' Orbitopathy
by Giulia Lanzolla, Francesca Saba, Silvia Corrias, Filippo Lixi, Giulia Faa, Alessandro Colleo, Chiara Mura, Gian Luigi Canu, Federico Cappellacci, Alberto Cuccu, Giuseppe Giannaccare, Stefano Mariotti, Francesco Boi
